E N D
Table S1 Univariate sub-group analysis, by histology, of the prognostic values of the factor landmark response (at 42 days post start of treatment) in relation to overall survival, showing hazard ratios (HR) and 95% confidence intervals (CI). Landmark response categories: progressive disease (PD), stable disease (SD) and partial response (PR).
Table S2 Univariate sub-group analysis, by platinum therapy, of the prognostic values of the factor landmark response (at 42 days post start of treatment) in relation to overall survival, showing hazard ratios (HR) and 95% confidence intervals (CI). Landmark response categories: progressive disease (PD), stable disease (SD) and partial response (PR).
Table S3 Univariate sub-group analysis, by combination therapy, of the prognostic values of the factor landmark response (at 42 days post start of treatment) in relation to overall survival, showing hazard ratios (HR) and 95% confidence intervals (CI). Landmark response categories: progressive disease (PD), stable disease (SD) and partial response (PR).
Table S4 Univariate sub-group analysis, by response evaluation criteria, of the prognostic values of the factor landmark response (at 42 days post start of treatment) in relation to overall survival, showing hazard ratios (HR) and 95% confidence intervals (CI). Landmark response categories: progressive disease (PD), stable disease (SD) and partial response (PR).